

Remarks

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

This submission is responsive to the Office Action mailed November 14, 2007, and the Advisory Action dated April 14, 2008. Because applicant's previously submitted response, dated March 12, 2008, was not entered, the claim amendments presented herein are relative to the claims presented as of October 4, 2007.

Claims 1, 15-18, 20-22, 24, 45-48, 56, and 57 have been amended, and claims 13 and 14 have been cancelled. Because the U.S. Patent and Trademark Office ("PTO") indicated in the outstanding office action that the subject matter of claims 13 and 14 are allowable, applicant has hereby amended independent claim 1 to recite that the GnRH analogue is conjugated to "a steroid hormone moiety or a progesterone derivative," wherein "the steroid hormone moiety is estradiol, progesterone, cortisol, corticosterone, estrone, testosterone or dihydroxytestosterone" (from original claim 13) and "the progesterone derivative is 11- α -hydroxyprogesterone or 21-hydroxyprogesterone" (from original claim 14). Claims 45 and 46, also independent, have been similarly amended. Therefore, no new matter has been introduced by the claim amendments.

Claims 1-11, 15-33, 35, 37, 39-41, 43, and 45-60 remain pending. No excess claim fees are due with this response.

The rejection of claims 1-11, 15-26, 29-33, 35, 37, 39-41, 43 and 45-60 under 35 U.S.C. § 112 (1st para.) as failing to comply with the written description requirement is overcome by the above amendments. As noted above, the allowable subject matter from claims 13 and 14 have been introduced into independent claims 1, 45, and 46. Because the PTO has already indicated that the specification provides adequate written descriptive support for the subject matter as presently claimed, applicant submits that the rejection of these claims under 35 U.S.C. § 112 should be withdrawn.

The objection to claims 13, 14, 27, and 28 is rendered moot by the above amendments, which overcome the sole remaining basis of rejection. Therefore, the objection should be withdrawn.

In view of all the foregoing, it is submitted that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: December 4, 2008

/Edwin V. Merkel/
Edwin V. Merkel
Registration No. 40,087

NIXON PEABODY LLP
1100 Clinton Square
Rochester, New York 14604-1792
Telephone: (585) 263-1128
Facsimile: (585) 263-1600